Edition:
India

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.01USD
15 Dec 2017
Change (% chg)

$0.02 (+1.85%)
Prev Close
$0.99
Open
$0.97
Day's High
$1.05
Day's Low
$0.97
Volume
614,950
Avg. Vol
171,957
52-wk High
$2.17
52-wk Low
$0.74

Select another date:

Thu, Nov 2 2017

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

BRIEF-Indivior says ‍durect, co sign $17.5 mln patent purchase deal

* DURECT AND INDIVIOR PLC SIGN A $17.5 MILLION PATENT PURCHASE AGREEMENT​

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

BRIEF-Durect Q2 loss per share $0.07

* Durect Corporation announces second quarter 2017 financial results and provides corporate update

BRIEF-Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

* Oradur-Methylphenidate ER capsule achieves primary endpoint in Phase 3 study in ADHD in Taiwan

BRIEF-Zogenix and Durect Corp enter into termination agreement

* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing

BRIEF-Durect says ‍on July 24, Impax Laboratories terminated asset transfer and license agreement dated Jan. 3, 2014​

* Durect - ‍on July 24, Impax Laboratories provided notice to co, that Impax is terminating asset transfer and license agreement dated January 3, 2014​

BRIEF-Durect completes enrollment in persist, phase 3 trial for Posimir

* Durect completes enrollment in Persist, phase 3 trial for Posimir

BRIEF-Durect's collaboration with Sandoz clears HSR review

* Durect's collaboration with Sandoz clears Hart-Scott-Rodino review and is effective

Select another date: